Clinical pharmacists to present on respiratory syncytial virus prevention; medication management

April 06, 2015

Clinical pharmacists from UMass Medical School’s Commonwealth Medicine division will present on the use of antibodies to reduce hospitalizations and emergency room visits in respiratory syncytial virus (RSV) patients, and medication management strategies for dual-eligible and substance abuse populations at the Academy of Managed Care Pharmacy’s 27th annual meeting and expo April 7-10 in San Diego.

Managed care pharmacists and residents from Commonwealth Medicine’s Clinical Pharmacy Services and Office of Clinical Affairs will present three posters during the annual meeting and expo.

A literature review of community-based interventions to improve oral medication regimen adherence among individuals with substance use disorders.
A systematic review that identifies the types of community-based interventions that improve oral medication adherence in patients diagnosed with substance use disorder. Concerns of poor medication adherence among this population may influence the decision by health care providers and payers to prescribe or manage a medication regimen requiring high adherence to optimize health care outcomes.

Mark Tesell, PharmD, BCPS, clinical consultant pharmacist team lead, Clinical Pharmacy Services
Tasmina Hydery, PharmD, clinical consultant pharmacist, Clinical Pharmacy Services
Karen Clements, ScD, MPH, senior project director, Center for Health Policy and Research

Evaluation of a pharmacist-led telephonic medication therapy management program on maintenance respiratory medication adherence in dual-eligible (Medicare and Medicaid) elderly members with asthma and/or chronic obstructive pulmonary disease.
An evaluation of the positive impact a pharmacist-led, telephonic, medication therapy management program can have on medication regimen safety and efficiency in dual-eligible members with asthma and/or chronic obstructive pulmonary disease (COPD). Medication non-adherence to maintenance respiratory medications results in poor health care outcomes and significant increases in health care costs in patients with these diagnoses.

Anna Bonfiglio, PharmD, managed care pharmacy resident, Clinical Pharmacy Services
Payal N. Kotadiya, PharmD, BCPS, clinical consultant pharmacist team lead, Clinical Pharmacy Services
Cheryl Catoggio, BA, BS, RPh, director of quality assurance, Clinical Pharmacy Services
Caroline Alper, MD, assistant professor of medicine, UMass Medical School
Karen Clements, ScD, MPH, senior project director, Center for Health Policy and Research
Donna M. Faber, PharmD, BCPS, clinical consultant pharmacist, Clinical Pharmacy Services
Neha Kashalikar, PharmD, clinical consultant pharmacist, Clinical Pharmacy Services
Mylissa Price, MPH, RPh, BCPS, associate director of clinical services, Clinical Pharmacy Services
Mito Takeshita, PharmD, clinical consultant pharmacist, Clinical Pharmacy Services

Impact of the 2014 American Academy of Pediatrics guidance for palivizumab prophylaxis on the incidence of respiratory syncytial virus and respiratory-related hospitalizations and emergency room visits in a Medicaid population.
An assessment of the impact palivizumab prophylaxis use had on the incidence of respiratory syncytial virus (RSV) and respiratory-related hospitalizations and emergency room visits for the 2014-2015 RSV season. Palivizumab is a monoclonal antibody approved by the U.S. Food and Drug Administration for the prevention of serious lower respiratory tract disease caused by RSV in children at high risk of infection. In July 2014, the American Academy of Pediatrics provided updated guidance on those patients who are most likely to receive benefit of palivizumab prophylaxis.

Jessica Duong, PharmD, managed care pharmacy resident, Clinical Pharmacy Services
Nicole Trask, PharmD, clinical consultant pharmacist, Clinical Pharmacy Services
Caroline Alper, MD, assistant professor of medicine, UMass Medical School
Karen Clements, ScD, MPH, senior project director, Center for Health Policy and Research
Donna M. Faber, PharmD, BCPS, clinical consultant pharmacist, Clinical Pharmacy Services
Pavel Lavitas, PharmD, BCPS, clinical consultant pharmacist, Clinical Pharmacy Services
Tom Pomfret, PharmD, MPH, BCPS, residency program director and clinical consultant pharmacist, Clinical Pharmacy Services
Mark Tesell, PharmD, BCPS, clinical consultant pharmacist team lead, Clinical Pharmacy Services
Kimberly Lenz, PharmD, clinical pharmacy manager, Office of Clinical Affairs
Justin Peristere, BS, RPh, associate program director for operations, Clinical Pharmacy Services
Paul L. Jeffrey, PharmD, pharmacy director, Office of Clinical Affairs